CClinicalTrials.gg
Not yet recruitingNCT05616182Updated Jan 24, 2024

Application of LARS Ligament in Bone Prosthesis Replacement

An observational study in Malignant Tumor, sponsored by Henan Cancer Hospital. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Henan Cancer Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.

Read the detailed description

This is a single-center prospective real-world observational study of 100 eligible patients with bone tumors who are scheduled to undergo LARS ligament implantation and/or bone prosthesis replacement in Henan Cancer Hospital in the next 10 years. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.

02

Conditions studied

  • Malignant Tumor

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 100 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Henan Cancer Hospital is the lead sponsor of 228 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing LARS ligament and bone prosthesis replacement

Inclusion criteria

Men and women of all ages are welcome.

Pathologically confirmed in our hospital as a subtype of malignant tumor.

He received LARS ligament and bone prosthesis replacement at our hospital.

Exclusion criteria

Exclusion Criteria:

Not Applicable.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • LARS ligament and bone prosthesis replacement was performed

    To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.

    Other: LARS ligament and bone prosthesis replacement was performed

Interventions

  • OtherLARS ligament and bone prosthesis replacement was performed

    To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    Complications of patients undergoing LARS ligament and bone prosthesis replacement.

    Time frame: From surgery to 24 months after surgery

  2. Limb function

    Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.

    Time frame: Patients were enrolled until 24 months after surgery

07

Study locations

1 site
  • Department of Bone and Soft Tissue ,Henan Cancer Hospital
    Zhengzhou, Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05616182
Lead sponsor
Henan Cancer Hospital
Responsible party
Wang Jiaqiang (associate chief physician, Henan Cancer Hospital) — Principal investigator
First posted
Nov 15, 2022
Start date
Dec 30, 2024 (estimated)
Primary completion
Feb 28, 2032 (estimated)
Completion
Feb 28, 2032 (estimated)
Last update
Jan 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion